New hope drug enters human testing for Tough-to-Treat cancers
NCT ID NCT05731271
Summary
This is the first study in people testing a new drug called TST003 for patients with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose, check for side effects, and see if the drug can help shrink tumors, especially in colorectal cancer. Patients receive the drug through an IV every three weeks and are monitored closely.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mary Crowley
Dallas, Texas, 75231, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
OHSU
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.